One could argue that despite all the big talk about combating the diabetes epidemic, lots of prominent organizations seem to be getting very little done. The field of diabetes education is facing a crisis, with so little professional support and funding to cope with the torrent of new patients coming their way.
For these reasons, I found it very encouraging to discover the Council for the Advancement of Diabetes Research and Education (CADRE), a non-profit organization "committed to reducing the devastating complications of both type 1 and type 2 diabetes through achievement of tight metabolic control. To achieve this goal, CADRE provides health care professionals with scientific information and educational programs to enable them to manage and empower their patients with diabetes."
Note the emphasis on REDUCING COMPLICATIONS. Note the focus on HELPING THE HEALTH PROS TO HELP PATIENTS. This seems practical and "meaty" enough to be meaningful. And there's more than just rhetoric on their website.
I browsed through the "resources" available for downloading, and found not only scientific journals and university webcasts ("The Evolution of Insulin Therapy," etc.) but also a detailed guide to "achieving and sustaining glycemic control in Type 2 diabetes," for example.
I also found an extremely thorough 64-slide presentation (!) on the importance of self-monitoring of blood glucose (SMBG). I would have thought this was crazy if I weren't so familiar with the voices speaking out against the value of glucose monitoring. What a relief to know that this high-value consortium at least is on our side here: current glucose monitors are good, very good. They help us manage this condition to live and enjoy a fulfilling life; newer, better monitors -- including continuous of course! -- will be even better, and even more vital to our well-being once they're perfected. Admittedly, CADRE is funded in part by the usual suspects: including Amylin Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, LifeScan, Merck & Co., Novartis, Novo Nordisk, Nutrition 21, Pfizer Inc., Sankyo Pharma, and Sanofi-Aventis. But I only count one actual meter company in that line-up.
Dr. Steven Edelman of TCOYD (Type 1 himself) recently announced a cooperation between the clinical journal Insulin and the CADRE organization. Having the utmost respect for him, I can only assume that all these groups' hearts and minds are in the right place. One small — or possibly middle-sized — step for improved diabetes education?
On that note, I'd also like to take the opportunity to congratulate Janis Roszler, CDE, author, and dLife expert on winning this year's AADE Educator of the Year Award. Congrats! Janis is something akin to our very own Dr. Ruth, so check her out when you get a chance.